See the DrugPatentWatch profile for yervoy
Yervoy, also known as ipilimumab, is a medication used to treat melanoma, a type of skin cancer. According to the American Cancer Society, Yervoy is a type of immunotherapy that works by helping the body's own immune system fight cancer cells [1].
Clinical trials have shown that Yervoy can be effective in treating melanoma. A study published in the New England Journal of Medicine found that Yervoy improved overall survival in patients with advanced melanoma when compared to a different treatment [2]. Another study published in the Journal of Clinical Oncology found that Yervoy plus a cancer vaccine extended survival in patients with advanced melanoma [3].
However, it's important to note that Yervoy, like all medications, can have side effects. The most common side effects of Yervoy include fatigue, diarrhea, and skin rash [1]. More serious side effects can also occur, such as liver problems, intestinal problems, and hormonal problems [1].
In terms of cost, Yervoy can be expensive. According to DrugPatentWatch.com, the price of Yervoy can vary depending on the dosage and treatment regimen, but it can cost thousands of dollars per dose [4]. It's worth noting that the cost of Yervoy may be covered by insurance, depending on the specific plan and coverage.
In summary, Yervoy has been shown to be effective in treating melanoma, but it can have side effects and can be expensive. Patients should talk to their doctor about the potential benefits and risks of Yervoy, as well as the cost and coverage options.
Sources:
[1] American Cancer Society. (2021). Ipilimumab. <
https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/ipilimumab.html>
[2] Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., ... & Chiarion-Sileni, V. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711-723.
[3] Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, H., Lesokhin, A. M., ... & Weber, J. S. (2013). Ipilimumab plus sargramostim versus ipilimumab alone for treatment of metastatic melanoma: a randomized, double-blind, phase 2 trial. Journal of Clinical Oncology, 31(22), 2780-2787.
[4] DrugPatentWatch.com. (n.d.). Ipilimumab. <
https://www.drugpatentwatch.com/drugs/ipilimumab>